Amylyx Pharmaceuticals Etf Profile
| AMLX Etf | USD 3.73 0.08 2.19% |
PerformanceVery Weak
| Odds Of DistressLow
|
Amylyx Pharmaceuticals is trading at 3.73 as of the 21st of March 2025; that is 2.19 percent increase since the beginning of the trading day. The etf's open price was 3.65. Amylyx Pharmaceuticals has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of January 2022 | Category Healthcare | Classification Health Care |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.. The company has 88.6 M outstanding shares of which 3.38 M shares are presently shorted by private and institutional investors with about 5.13 trading days to cover. More on Amylyx Pharmaceuticals
Moving against Amylyx Etf
Amylyx Etf Highlights
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering Amylyx Pharmaceuticals report their recommendations after researching Amylyx Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Amylyx Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Amylyx Pharmaceuticals. The Amylyx consensus assessment is calculated by taking the average forecast from all of the analysts covering Amylyx Pharmaceuticals. | |
| Tax Provision | (393,000) |
| Logo U R L | imglogosUSAMLX.png |
| Total Current Liabilities | 28.41 Million |
| Total Stockholder Equity | 164.76 Million |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 33.04 Million |
| Property Plant And Equipment Net | 2.73 Million |
| Begin Period Cash Flow | 170.92 Million |
| Net Debt | (75.41 Million) |
| Accounts Payable | 2.94 Million |
| Cash | 77.39 Million |
| Other Operating Expenses | 402.1 Million |
| Non Current Assets Total | 4.2 Million |
| Non Currrent Assets Other | 1.47 Million |
| Forward Price Earnings | 2.7739 |
| Cash And Short Term Investments | 176.5 Million |
| 50 Day M A | 3.5127 |
| Code | AMLX |
| Common Stock Shares Outstanding | 68.14 Million |
| Liabilities And Stockholders Equity | 193.63 Million |
| Country Name | USA |
| Net Interest Income | 13.81 Million |
| Capital Lease Obligations | 1.98 Million |
| E P S Estimate Next Year | (2.16) |
| Investments | 75.65 Million |
| Other Current Assets | 12.48 Million |
| Free Cash Flow | (167.8 Million) |
| Net Invested Capital | 164.76 Million |
| E P S Estimate Current Year | (2.26) |
Amylyx Pharmaceuticals [AMLX] is traded in USA and was established 2018-03-26. Amylyx Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The fund is listed under Health Care category and is part of Pharmaceuticals family. Amylyx Pharmaceuticals presently have 193.63 M in assets under management (AUM).
Amylyx Pharmaceuticals currently holds about 206.68 M in cash with (167.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.53.
Check Amylyx Pharmaceuticals Probability Of Bankruptcy
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Amylyx Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Amylyx Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Amylyx Pharmaceuticals Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top Amylyx Pharmaceuticals Etf Constituents
| WES | Western Midstream Partners | Stock | Energy | |
| VNOM | Viper Energy Ut | Stock | Energy | |
| GEL | Genesis Energy LP | Stock | Energy | |
| NGL | NGL Energy Partners | Stock | Energy | |
| PAGP | Plains GP Holdings | Stock | Energy | |
| MPLX | MPLX LP | Stock | Energy | |
| CQP | Cheniere Energy Partners | Stock | Energy |
Amylyx Pharmaceuticals Major Institutional Holders
| Instituion | Recorded On | Shares | |
| Nantahala Capital Management, Llc | 2024-12-31 | 1.5 M | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 1.3 M | |
| Saturn V Capital Management Llc | 2024-12-31 | 889.1 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 868.4 K | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 823.4 K | |
| Qube Research & Technologies | 2024-12-31 | 780.6 K | |
| Jane Street Group Llc | 2024-12-31 | 765.5 K | |
| Fmr Inc | 2024-12-31 | 731.4 K | |
| Two Sigma Investments Llc | 2024-12-31 | 651.5 K | |
| Perceptive Advisors Llc | 2024-12-31 | 6.8 M | |
| Tcg Crossover Management, Llc | 2024-12-31 | 4.6 M |
Amylyx Pharmaceuticals Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Amylyx Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.2238 | |||
| Treynor Ratio | (0.13) |
Amylyx Pharmaceuticals Against Markets
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.